All 21 committee members voted to approve the biologic as a treatment for ulcerative colitis and 20 of 21 committee members voted for approval as a Crohn’s disease treatment.
The advisory committees’ decision is non-binding, but will be taken into consideration when the FDA makes its decision on Takeda Pharmaceutical’s Biologics License Application for vedolizumab.
More Articles on Gastroenterology:
Norwalk Hospital Adds Dr. Summa S. Magge
FDA Advisory Committee Reviews Vedolizumab Safety Concerns
Joint Research Team Discovers New Method for Developing Anti-Diarrheal Drugs
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
